help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McLachlan, R. I.
Right arrow Articles by Soules, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McLachlan, R. I.
Right arrow Articles by Soules, M. R.

Journal of Clinical Endocrinology & Metabolism, Vol 68, 1078-1085, Copyright © 1989 by Endocrine Society


ARTICLES

The importance of luteinizing hormone in the control of inhibin and progesterone secretion by the human corpus luteum

RI McLachlan, NL Cohen, WW Vale, JE Rivier, HG Burger, WJ Bremner and MR Soules
Department of Medicine, University of Washington, Seattle 98195.

Serum inhibin levels rise markedly during the luteal phase of the human menstrual cycle and are closely correlated with serum progesterone (P) levels, suggesting that the corpus luteum (CL) secretes inhibin. While FSH is the major regulator of inhibin secretion by the granulosa cells, the control of CL inhibin secretion is unclear. We hypothesized that, like P, CL inhibin secretion would be LH dependent. To examine this possibility, normal women were given the GnRH antagonist [Ac-D2Nal1, D4CL Phe2, D3Pal3, Arg5, DGlu6 (AA), DAla10]GnRH (Nal-Glu antagonist) for 3 consecutive days commencing on day 6-8 of the luteal phase. The daily doses were 2.5 (n = 3), 10 (n = 4), and 25 micrograms/kg (n = 5), sc. Serum LH levels fell 2 h after injection, and the fall was maximal (70-74%) at 6 h; the degree of suppression was not dose dependent. The duration of suppression was dose related, being less than 12 h, between 12, and 24 h, and more than 24 h for the 2.5, 10, and 25 micrograms/kg doses, respectively. Serum FSH levels declined by 22-43%, but the effect was not dose related. Serum P levels fell by 42-45% 8 h after each dose of antagonist. They returned to baseline 24 h after the 2.5 micrograms/kg dose, but after both the 10 and 25 micrograms/kg doses serum P levels continued to fall, and menstrual bleeding commenced within 48-72 h after the first antagonist injection. Serum inhibin levels were not altered relative to normal cycles by the 2.5 micrograms/kg dose, but fell by 48% and 58%, and 62% and 73% respectively, 48 and 72 h after the 10 and 25 micrograms/kg doses, respectively. Serum P and inhibin levels correlated closely in all women. To examine the relative roles of FSH and LH in the control of CL function, Nal-Glu antagonist (25 micrograms/kg, sc) was administered at 0 and 24 h commencing on day 6-8 of the luteal phase, in combination with either human menopausal gonadotropin (hMG; 150 IU, im, every 12 h) or hCG (1500 IU, im, once), both commencing at 0 h. hMG administration led to a rapid (by 2 h) and marked (3- to 9-fold) rise in serum FSH levels, whereas serum LH remained low, similar to antagonist alone treatment cycless.(ABSTRACT TRUNCATED AT 400 WORDS)


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
W. S. Dhillo, O. B. Chaudhri, E. L. Thompson, K. G. Murphy, M. Patterson, R. Ramachandran, G. K. Nijher, V. Amber, A. Kokkinos, M. Donaldson, et al.
Kisspeptin-54 Stimulates Gonadotropin Release Most Potently during the Preovulatory Phase of the Menstrual Cycle in Women
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3958 - 3966.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Xiao, L. Xia-Zhang, and M. Ferin
Inadequate Luteal Function Is the Initial Clinical Cyclic Defect in a 12-Day Stress Model that Includes a Psychogenic Component in the Rhesus Monkey
J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2232 - 2237.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
B. E. Friden, E. Runesson, M. Hahlin, and M. Brannstrom
Evidence for nitric oxide acting as a luteolytic factor in the human corpus luteum
Mol. Hum. Reprod., May 1, 2000; 6(5): 397 - 403.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. B. Seminara, M. Beranova, L. M. B. Oliveira, K. A. Martin, W. F. Crowley Jr., and J. E. Hall
Successful Use of Pulsatile Gonadotropin-Releasing Hormone (GnRH) for Ovulation Induction and Pregnancy in a Patient with GnRH Receptor Mutations
J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 556 - 562.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
C. K. Welt, J. M. Adams, P. M. Sluss, and J. E. Hall
Inhibin A and Inhibin B Responses to Gonadotropin Withdrawal Depends on Stage of Follicle Development
J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2163 - 2169.
[Abstract] [Full Text]


Home page
Physiol. Rev.Home page
J. A. McCracken, E. E. Custer, and J. C. Lamsa
Luteolysis: A Neuroendocrine-Mediated Event
Physiol Rev, April 1, 1999; 79(2): 263 - 323.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. J. Hayes, J. E. Hall, P. A. Boepple, and W. F. Crowley Jr.
Differential Control of Gonadotropin Secretion in the Human: Endocrine Role of Inhibin
J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1835 - 1841.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society